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Streptococcus agalactiae
in Relapsing Cellulitis
To the Editor—We read with interest
the report by Del Giudice et al. [1] about
a case of relapsing erysipelas caused by
Streptococcus agalactiae. Molecular analy-
ses of the strains, which were isolated from
skin and vaginal specimens during 2 ep-
isodes, revealed identical restriction pat-
terns, leading the authors to suggest that
vaginal carriage of S. agalactiae served as
a reservoir for relapsing skin infection.
Nevertheless, the detailed pathogenesis of
relapsing cellulitis/erysipelas has not been
fully elucidated. We report a case of fas-
ciitis that was followed by 4 episodes of
cellulitis, and we discuss an additional
mechanism of recurrence.
A 38-year-old, previously healthy
woman presented with fever, chills, and
severe pain in the left leg. Clinical ex-
amination of the extremity revealed
edematous erythema with pronounced
tenderness. MRI delineated a fluid col-
lection between the subcutaneous tissue
and the fascia. Wide debridement was
performed immediately, and intravenous
antimicrobial treatment (amoxicillin-
clavulanate, 2.2 g 3 times per day, plus
clindamycin, 600 mg 3 times per day)
was administered. Gram-positive cocci in
chains were abundant throughout the tis-
sue specimens, but they failed to grow on
culture. Broad-spectrum PCR and blood
culture results remained negative. The
patient’s subsequent clinical course was
favorable, but lymphedema persisted at
the infection site.
During the subsequent 2 years, cellulitis
occurred in the same area 4 times (7, 15,
17, and 24 months after the occurrence of
fasciitis). S. agalactiae grew in blood cul-
tures during the first and fourth episodes
of cellulitis and from a vaginal swab cul-
ture during the third episode of cellulitis.
Extensive investigations, including echo-
cardiography, gynecological, and immu-
nological examinations, revealed neither
the source of bacteremia nor evidence of
primary or secondary immunosuppres-
sion. The infections resolved after 8–14
days of intravenous penicillin (plus ami-
noglycosides during 2 episodes). After the
third episode, a 5-month prophylactic
course of amoxicillin (750 mg 3 times
per day) was initiated. Two months after
completion of the amoxicillin regimen,
the cellulitis relapsed. SmaI digestion of
the strains isolated from the vagina (third
episode) and blood (fourth episode), fol-
lowed by PFGE, revealed identical re-
striction patterns. The patient is currently
being treated with a second course of
long-term oral prophylaxis.
Our case and the reported cases of re-
lapsing cellulitis/erysipelas due to S. aga-
lactiae involved a skin region affected by
chronic lymphedema [1–3], which is
strongly associated with recurrent strep-
tococcal infection [4]. Lymphatic tissue
alterations may lead to locally impaired
immune responses and insufficient bac-
terial clearance. Therefore, spread from
vaginal colonization may not be the only
explanation for multiple relapses. In situ
persistence of microorganisms in non-
professional phagocytes can cause re-
lapsing infection, as shown with Staph-
ylococcus aureus [5, 6]. Furthermore,
analyses of biopsy specimens obtained
from persons with severe soft-tissue in-
fection have revealed significant amounts
of viable Streptococcus pyogenes, despite
the administration of antibiotics, up to
14 days after disease onset [7]. Group B
streptococci can interact with extracel-
lular matrix components of eukaryotic
cells and may invade fibroblasts and ep-
ithelial and endothelial cells [8]—find-
ings that could support our hypothesis
of in situ persistence. This does not con-
flict with the results of the study by Del
Giudice et al. [1], but it might contribute
an additional possible mechanism in re-
current cellulitis/erysipelas. Intracellular
persistence of viable group A streptococci
in erysipelas is currently being analyzed
at our center [9].
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Does the Nose Know?
The Odiferous Diagnosis
of Clostridium difficile–
Associated Diarrhea
To the Editor—Clostridium difficile–as-
sociated diarrhea (CDAD) is a common
and emerging problem in hospitals; pa-
tients present with clinical symptoms of
leukocytosis and abdominal pain, and the
disease is associated with significant mor-
bidity and mortality [1]. Diagnosis relies
on various modalities, including labora-
tory tests (e.g., tissue culture or ELISA),
invasive procedures (e.g., colonoscopic ex-
amination) and, at times, clinical suspi-
cion and response to empirical treatment
[2]. An “urban legend” exists among nurs-
ing specialties that CDAD has a unique
odor that would allow for olfactory di-
agnosis; however, this has never been sci-
entifically tested. A majority of nurses in-
terviewed in preparation for this study
were quite confident in their ability to
make a positive diagnosis of CDAD on
the basis of olfactory examination.
Physician requests for stool analysis for
C. difficile toxin were reviewed at 2 sep-
arate teaching hospitals in Dayton, Ohio,
over a 6-month period. Nursing staff were
interviewed, and a survey (including ques-
tions regarding nursing demographic data
and specific stool-related data) was com-
pleted before stool test results were avail-
able. Nurses were included if they had the
“perceived” ability to diagnose CDAD by
smell and were directly involved in the
processing or examination of the patient’s
stool. Nurses were excluded from the
study if their patients were receiving em-
pirical therapy with either metronidazole
or oral vancomycin for 124 h. CDAD was
diagnosed by standard testing in the hos-
pital laboratory (i.e., by ELISA or tissue
culture).
A total of 138 nursing staff surveys were
completed. Sensitivity and specificity for
the odiferous diagnosis of CDAD were
0.55 (95% CI, 0.33–0.77) and 0.83 (95%
CI, 0.76–0.90), respectively. The positive
predictive value and negative predictive
value were 0.35 (95% CI, 0.19–0.52) and
0.92 (95% CI, 0.86–0.97), respectively. The
overall accuracy of the nurses in diagnos-
ing or excluding CDAD was 79%. Length
of nursing experience did not impact the
nurses’ ability to diagnose; however, stool
quality (i.e., whether the stool was partially
formed or formed) did impact the accu-
racy of the diagnosis.
This study suggests that nursing staff
were able to exclude a diagnosis of CDAD
with a high degree of confidence and ac-
curacy. However, confirmation of the di-
agnosis on the basis of odor and stool
quality was insensitive.
Results of this preliminary study, if con-
firmed, may have a broad impact on the
approach to treatment of hospitalized pa-
tients who develop diarrhea. The odifer-
ous characteristics associated with the
stool of patients with CDAD may impact
decisions regarding the initiation of em-
pirical therapy (perhaps limiting the over-
use of antibiotics, such as metronidazole),
infection-control practices (limiting un-
necessary patient isolation), and the ne-
cessity for stool testing for CDAD; more-
over, these findings may possibly lead to
new diagnostic modalities, such as an
“electronic sniffer” [3].
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